Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure
Renae Walsh, Rachel Hammond, Lilly Yuen, Joshua Deerain, Tanya O'Donnell, Thomas Leary, Gavin Cloherty, Anuj Gaggar, Kathryn Kitrinos, Mani Subramanian, Darren Wong, Stephen Locarnini
LIVER INTERNATIONAL | WILEY | Published : 2019
BACKGROUND AND AIM: Functional cure is the major goal of chronic hepatitis B (CHB) therapy though few biomarkers predict this outcome. HBsAg epitope occupancy can be influenced by therapeutic and immune pressure. The aim of this study was to map the HBsAg epitope profiles during long-term nucleos(t)ide analogue therapy in patients with genotype A CHB, in the context of HBsAg loss (SL)/seroconversion. METHODS: We evaluated 25 genotype A CHB patients in the GS-US-174-0103 trial of HBeAg-positive CHB patients treated with tenofovir or adefovir for 4 years, 14 who achieved SL whilst 11 had no change. We epitope mapped the major domains of HBsAg to identify those patients with HBsAg clearance pro..View full abstract
Awarded by Gilead Sciences
Gilead Sciences funded and conducted the original GS-US-174-0103 clinical trial, including the collection and storage of serum samples. For the study described here, all clinical data were made available to the investigators. Neither Gilead Sciences nor Abbott Laboratories were involved in the analysis or interpretation of data, the decision to submit for publication, and did not fund the study.